BMI status influences the response of insulin sensitivity to diacylglycerol oil in Chinese type 2 diabetic patients.
Present study was a post-hoc analysis and aimed to examine the influence of adiposity status on the response of insulin sensitivity to diacylglycerol (DAG) oil in type 2 diabetic patients. A total of 127 type 2 diabetic patients were recruited into a randomized double-blind controlled parallel trial in Hangzhou, China. Subjects were allocated to consume the same amount (25 mL/d) of DAG (n=66) or triacylglycerol (TAG) oil (n=61) with similar fatty acid compositions for 120 days. Marginally significant interaction was observed between BMI status (overweight versus normal weight) and test oils for fasting insulin (p-interaction=0.046) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (p-interaction=0.059). For normal weight subjects (BMI<=25), DAG group showed significant decrease of fasting insulin (-2.0, 95% CI: -3.90, -0.10; p=0.036) and HOMA-IR (-0.69, 95% CI: -1.36, -0.03; p=0.015), but not in the TAG group. No significant change of either trait in DAG or TAG group was observed for overweight subjects (BMI>25). In summary, the effect of DAG oil on insulin sensitivity in type 2 diabetic patients is influenced by the baseline BMI status. Type 2 diabetic patients may benefit from DAG oil in terms of insulin sensitivity improvement, however only when they are in normal body weight range.
Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China.
Ju-Sheng
JS
Zheng
College of Food Science and Technology, Huazhong Agricultural University, Wuhan, China.
Ling
L
Wang
Wuhan Puai Hospital, Tongji Medical College, Wuhan, China.
Mei
M
Lin
Wuhan Puai Hospital, Tongji Medical College, Wuhan, China.
Hong
H
Yang
Department of Food Science and Nutrition, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China. Email: duoli@zju.edu.cn.
Duo
D
Li
D000328:Adult; D000368:Aged; D015992:Body Mass Index; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D004075:Diglycerides / Q000008:administration & dosage*; D004311:Double-Blind Method; D005227:Fatty Acids / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D014280:Triglycerides / Q000008:administration & dosage
D004042:Dietary Fats, Unsaturated; D004075:Diglycerides; D005227:Fatty Acids; D014280:Triglycerides